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Short Title: Silencing of human Huntingtin in transgenic sheep 
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Abstract: Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a genetic 
expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models 
have shown that artificial miRNAs can reduce mutant HTT but evidence for their effectiveness 
and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT 
with 73 CAG repeats. We used AAV9 to unilaterally deliver to HD sheep striatum an artificial 
miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters- 
U6 or CβA. The treatment reduced human mutant (m) HTT mRNA and protein 50-80% in the 
striatum at one and six-months post-injection. Silencing was detectable in both caudate and 
putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant 
loss of neurons labeled by DARPP32 or NeuN at six months after treatment, Iba1-positive 
microglia were detected at control levels. We conclude that safe and effective silencing of human 
mHTT protein can be achieved and sustained in a large animal brain by direct delivery of an 
AAV carrying an artificial miRNA. 
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Introduction 
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of 
the CAG repeat region in the huntingtin (HTT) gene. The HTT gene, which was discovered in 
19931, encodes a ~350 kDa protein comprising a 17 amino acid N-terminal region, followed by 
the CAG repeat, a polyproline repeat region, and a series of α-helical HEAT (Huntingtin, 
elongation factor 3, protein phosphatase 2A and TOR1) repeats2. Gene-silencing therapeutics, 
which include methods targeting RNA (antisense oligonucleotides, siRNAs, artificial miRNAs) 
and DNA (CRISPR/Cas9, Zinc finger nucleases) are promising as they are directed to the most 
proximal cause of HD, the HTT mRNA or gene itself. Studies in HD mouse models support the 
feasibility of reducing the levels of the HD gene and its protein in brain using antisense 
oligonucleotides, siRNAs, shRNAs and miRNAs 3–12. Intrathecal delivery of an antisense 
oligonucleotide against HTT is currently being tested for safety in humans 13 but may have 
limited effect in the caudate-putamen 7. Long-lasting expression of shRNAs or artificial 
microRNAs can be achieved in the brain using a viral delivery approach and direct injection with 
stereotactic methods.  Recombinant adeno-associated virus (rAAV) has been shown to safely 
deliver its cargo to neurons and other cell types in the striatum of mice 14–16. Compared to an 
antisense approach, the advantage of AAV is that it is episomal and can be indefinitely active. 
Promoter choice determines expression levels of the AAV cargo, which may be an important 
determinant of the safety and silencing activity of potential RNAi therapies for HD 17,18. 
A challenge in advancing human gene therapy for HD is scaling of therapeutics to a capacity that 
is comparable to treating humans. The sheep brain is significantly larger than that of mice and 
with a structure more similar to humans than are rodents. Recently we showed that AAV-GFP 
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could be accurately delivered to the neostriatum of normal Dorset sheep using an image guided 
approach and convection enhanced delivery 19,20. HD transgenic sheep express the full-length 
human HTT cDNA with 73 CAG repeats from the human HTT promoter 21. They exhibit a slow 
disease progression. Only a small number of animals have been analyzed to date, but reduced 
cannabinoid receptor type 1 (CB1) and DARPP-32 immunoreactivity has been reported in a 
single 7 month old animal.21 At six months, there is a decrease in gamma-aminobutyric acid A 
receptor alpha 1 (GABAA α1) immunostaining in the caudate nucleus and the putamen and a 
decrease in leu-enkaphalin (Leu-ENK) in the globus pallidus22. There are no detectable changes 
in immunostaining for glial fibrillary acidic protein (GFAP), a marker for astrogliosis, up to 36 
months22. Sparse cortical huntingtin aggregates appear by 18 months of age and nuclear 
inclusions have been reported at 36 months22. Young animals show no obvious behavioral 
phenotypes, but subtle disruptions in circadian rhythms appear by 18 months of age.23   In this 
study, we report safe and successful targeting of full-length human HTT mRNA in a large animal 
model of HD, a necessary first step in the treatment of patients with HD. 
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Materials and Methods 
Animals and animal procedures 
Merino sheep were bred at the South Australia Research and Development Institute 
(Rosedale, SA) and transferred to the South Australia Health and Medical Research 
Institute (Gilles Plains, SA) approximately 3 weeks prior to surgery.  The sheep were 
provided with food and water as needed and were cared for according to the guidelines of 
the South Australia Health and Medical Research Institute (approval number 146/13) and 
the Primary Industries and Regions South Australia (10/13) animal ethics committees.  
Prior to the administration of anesthetic, the animals were fasted overnight for 
approximately 8 hours. Animals were given a pre-operative physical including heart rate, 
respiratory rate, temperature and weight.  Baseline samples of serum (5ml) and 
cerebrospinal fluid (CSF) were collected. 
The study was conducted in two parts with two different cohorts of sheep. For the first 
study, forty-one transgenic animals (21 Wethers, 20 Ewes), aged approximately 8 months 
were injected unilaterally with 300µl of self-complementary AAV9 (scAAV9) vector at a 
titer of 1x1013 gc/ml for a total of 3x1012 genome copies. Animals weighed between 39kg 
and 55kg at the time of injection. For the second study, fourteen animals aged 14 months 
were injected with this vector and fourteen with the control vector. At this time, animals 
weighed between 52kg and 79kg. Gadolinium was added to the vector formulation to 
allow post-surgical imaging of the injection spread. The animals were moved to the 
operating room and prepped for surgery.  Buprenorpine and carprofen were administered 
and animals were anesthetized using ketamine and diazepam. Animals were maintained 
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under isoflurane during the surgery. They were rested in the sphinx position on a foam 
cushion on folded extremities or with extremities dangling.  A stereotactic frame (Kopf, 
large animal) was used to hold the animal’s head in place.  Cerebrospinal fluid was 
collected via lumbar puncture using a 19-gauge spinal tap cannula.  The rAAV was 
delivered directly to the striatum, targeting the internal capsule. The animal’s head was 
shaved, prepped with betadine, and draped with clear plastic.  A curvilinear incision was 
made using a #15 scalpel to expose the bregma.  Once the bregma was identified, a 3 – 
4mm burr hole was placed 10mm rostral to the bregma and 11mm lateral of the midline 
using an electric drill.  The convection enhanced delivery (CED) cannula (MRI 
Interventions, Irvine, CA) was secured in the manipulator and primed with agent to be 
injected to remove air from the line.  The dura was opened with a 1.5mm incision using a 
#11 scalpel and the CED cannula was advanced 25mm from dural surface to the target 
depth.  The outer cannula (1.65mm) sealed the dural incision to prevent CSF leakage 
during the infusion. The infusion began 5 minutes after cannula insertion to allow for 
tissue around the tip to stabilize.  The infusion rate was set at 3.33µl/minute until a total 
volume of 300µl was injected.  Ten minutes after infusion was completed the cannula 
was slowly withdrawn and a bone wax plug was used to repair skull and prevent CSF 
leakage.  The wound was cleansed with saline and closed using a 3.0 vicryl suture. 
Standard anesthesia wake-up and recovery procedure was followed, according to 
guidelines at the South Australia Health and Medical Research Institute. Post-surgery 
MRI was performed to determine the spread of gadolinium. One animal from the first 
study was excluded following surgery because no gadolinium was visible upon imaging 
and a second animal from the second study was excluded because the gadolinium 
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appeared to be primarily in the ventricle. After the surgery, the animals were kept under 
observation for three days and housed indoors for five days. They were then transferred 
and housed outdoors in paddocks for the remainder of the study. They were monitored 
visually for signs of distress and changes in behavior throughout the study. Two animals 
suffered surgical complications, resulting in partial limb paralysis. This was thought to be 
due to the positioning of the animals under anesthesia. One was euthanized early and one 
was moved from the six month to the one-month cohort. Animals were weighed 
periodically throughout the post-injection period and samples of CSF, blood and serum 
were taken and saved for further analysis.    
For cell counts and differentials, blood was collected via jugular venipuncture into a 
potassium EDTA blood collection tube (Lavender top; LT) and delivered to the 
Automated Directorate (SA Pathology, Royal Adelaide Hospital, Adelaide, Australia) for 
a complete blood examination with differential (CBE differential). For clinical chemistry 
blood was collected via jugular venipuncture into a serum collection tube (red top; RT). 
The samples were submitted to SA Pathology for multiple biochemical analysis (MBA). 
At one and six-months post-injection animals were harvested, with animals being used 
for either histology or biochemical analysis. Animals were transported to operating table 
and placed in ventral recumbency while approximately 6ml of CSF was collected.  The 
animal was repositioned in dorsal recumbency. The carotid arteries were exposed and 
cannulated at a depth of 4cm from the tip of the cannula.  The jugular veins were exposed 
and 200-500 U Heparin/kg were injected into the jugular vein.  Five minutes after 
administering the Heparin, sheep were euthanized by intravenous injection of Lethabarb 
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(325mg pentabarbitone sodium/ml) at 1 ml/2kg of body weight. The infusion pump was 
primed with cold 9% NaCl and connected to the carotid cannulas. For 
immunohistochemical analysis, the animal was perfused with approximately 8 liters of 
cold 9% NaCl at a pressure of 500mmHg followed by infusion with 8 liters 4% 
paraformaldehyde at a pressure of 500mmHg.  The brain and liver were extracted.  The 
tissues were post-fixed in 4% paraformaldehyde for 24 hours at 4˚C and transferred to 
30% sucrose in 1x phosphate buffered saline for a minimum of 14 days at 4˚C 
For RNA, protein, and DNA assays, sheep were perfused with cold 9% NaCl as 
described above. Collection of the peripheral tissue was performed in the following 
order:  liver, adrenal gland, ovaries (if applicable), muscle, and heart.  Cross 
contamination was prevented by the use of different instruments and washing necropsy 
surfaces with 10% bleach and 70% ethanol.  The organ was removed from the body and 
harvested using a 3mm biopsy punch or cut to size using a scalpel.  A total of ten samples 
were collected from each organ; two samples were snap frozen in liquid nitrogen and 
eight samples were stored in RNAlater (Sigma-Aldrich) at 4˚C for 24 hours (300µl of 
RNAlater for liver, muscle and heart samples, 500µl of RNAlater for adrenal gland and 
ovary samples).  
The brain was removed from the skull using an oscillating saw and bone forceps. After 
extraction, the brain was weighed and placed ventrally in a custom made plexiglass brain 
matrix (University of Massachusetts Machine Shop). Nine cuts were made to the brain to 
fully contain the striatum in four 6mm blocks.  The first cut was made posterior to the 
olfactory bulb attachment (approximately 18mm from the beginning of the matrix) and 
10 
 
the subsequent four cuts were made at 6mm intervals (Figure S1A). The striatum was 
divided into four 6 mm blocks from posterior to anterior: 2p (posterior), 2m1 (medial 1), 
2m2 (medial 2) and 2a (anterior). The striatal dissection was performed in the following 
order: 2p, 2m1, 2a.  The striatum in the right (non-injected) hemisphere was dissected 
first in all blocks and scalpel blade was changed between hemispheres.  The dissection 
was performed in a petri dish on dry ice and care was taken to remove as much white 
matter from the striatal tissue as possible.  Once dissected out, the striatal pieces (caudate 
and putamen) were split in half; with the medial piece (closest to midline of block) stored 
in 1ml of RNAlater at 4˚C and the lateral piece snap frozen in liquid nitrogen.  The 
striatal dissection for the six-month cohort in the CΒA study was done in a manner to 
produce four striatal samples from both the caudate and putamen.  The dorsal sections 
(both medial and lateral) were snap frozen in liquid nitrogen and the ventral sections 
(both medial and lateral) were stored in 1ml of RNAlater at 4˚C.  RNAlater was removed 
after twenty-four hours and samples were stored at -80˚C.   
The 2m2 block was generously covered with OCT and frozen in a 2-methylbutane and 
dry ice bath.  The remainder of the 2a, 2m1, and 2p block was frozen in the same manner.  
Ten cortex samples were taken from each block in a dorsal to ventral manner; two were 
snap frozen in liquid nitrogen and eight were stored in 1ml RNAlater at 4˚C.   
Sectioning of tissue for histological analysis 
Prior to tissue sectioning for histological analysis the striatum was isolated from the fixed and 
sucrose infiltrated brain, generously covered with OCT, and stored at -20˚C for twenty-four 
hours.  Coronal sections measuring 40µm thick were cut with a sliding microtome (Reichert-
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Jung Tetrander sliding microtome) through the entire striatum.  The sections were stored in 
0.01% sodium azide in 1x phosphate buffered saline at 4˚C. 
Vector cloning and rAAV9 Production 
For the first study, the test vector contained a U6 promoter driving an artificial miRNA 
based on the endogenous mir155 backbone (AAV9-U6-miRHTT). The artificial miRNA 
targets human, but not the sheep huntingtin and has previously been described 17. A 
chimeric cytomegalovirus enhancer/chicken Β-actin (CΒA) promoter driving a chimeric 
intron was included to improve AAV packaging. The control vector (AAV9) contained 
only the empty CΒA promoter and the intron. For the second study, the test vector 
contained the CMV enhancer and CΒA promoter, the intron and the miRNA-155 based 
artificial miRNA (AAV9-CΒA-miRHTT).  
For packaging, the rAAV vector plasmid, a packaging plasmid and an adenovirus helper 
plasmid were co-transfected into HEK 293 cells. The packaging plasmid expresses the 
regulatory and AAV9 capsid proteins leading to excision, replication and packaging of 
the recombinant genome from the rAAV vector plasmid into AAV virions. The 
recombinant viruses were purified by standard CsCl gradient sedimentation and desalted 
by dialysis  
Analysis of Huntingtin mRNA Levels 
The RNA levels in the RNAlater preserved samples were analyzed using a branched 
DNA assay (bDNA)24.  Samples were processed according to the manufacturer’s 
guidelines for preparation of tissue homogenates from tissues stored in RNAlater 
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(Affymetrix eBioscience, Quantigene® Sample Processing Kit).  The homogenized 
samples were analyzed according to the manufacturer’s guidelines for the bDNA assay 
(QuantiGene® 2.0 Reagent System).  The samples were analyzed with a probe to detect 
human huntingtin (Human HD, SA-50339 from Quantigene), ovine huntingtin (Sheep 
Huntingtin, SF-10586 from Quantigene), and ovine calnexin as a housekeeping gene 
(Sheep Calnexin, SF-10622 from Quantigene).  The assay results were measured with a 
Tecan Infinite M1000 PRO luminometer (integration time set at 200ms). 
Vector Genome Distribution 
Genomic DNA was extracted from samples that had been snap frozen in liquid nitrogen 
using the Gentra Puregene Tissue kit (Qiagen).  The genomic DNA concentrations were 
measured using the NanoDrop ONEc spectrophotometer.  Droplet Digital PCR (ddPCR, 
Biorad) was performed according to the manufacturer’s recommendations, using 50ng of 
DNA as input and TaqMan assays detecting a region of the CB promoter common to all 
vectors and the HPRT reference gene.  Results are expressed as vector genome per 
diploid genome (vg/dg). 
Analysis of Huntingtin Protein Levels—Sample preparation 
Small pieces of tissue were removed from frozen blocks and homogenized on ice in 200 
µl 10mM HEPES pH7.2, 250mM sucrose, 1mM EDTA + protease inhibitor tablet (mini, 
complete, EDTA-free Roche #11836170001). Samples were sonicated for 10 seconds and 
protein concentration was determined using the Bradford method (BioRad #500-0006). 
Mesoscale Detection Assay (MSD) for mHTT protein 
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A 96-well QuicPlex standard plate (MSD) was coated with rabbit monoclonal anti-HTT 
proline 1220 region antibody (D7F7, Cell Signaling, 1:250) in PBS, overnight at 4°C. 
The plate was washed 3x 10 min with PBST (PBS + 0.05% Tween20) and blocked with 
3% bovine serum albumin (BSA) in PBS for 2 hours at RT. After washing 3x 10 min 
with PBST, technical duplicates of samples with 20 µg of protein in 25 µl of 
homogenization buffer or blanks (homogenization buffer) were distributed into the plate 
and incubated overnight at 4°C on an orbital shaker. The plate was washed 3x 10 min in 
PBST and incubated in secondary/detection antibody mix as follows: For detection of 
mHTT, mouse monoclonal anti-polyQ antibody MW1 (DSHB) was mixed with anti-
mouse SulfoTag detection antibody (MSD) at 1 µg/ml of each antibody in 1% BSA in 
PBS. 30 µl of detection antibody mix was applied per well and incubated for 3 hours at 
RT on an orbital shaker. The plate was washed 3x 10 min in PBST and 150 µl of 2x Read 
Buffer (MSD) was applied per well right before readout on QuickPlex SQ120 (MSD).  
Western Blotting 
Equal concentrations of protein (25 µg) were separated by SDS-PAGE on 3-8%Tris-
Acetate gels (Life Technologies #EA03785BOX) and transferred to nitrocellulose using 
TransBlot Turbo (BioRad).  Blots were blocked in 5% non-fat dry milk in Tris-buffered 
saline + 0.1% Tween-20 (TBST) for 1 hour and incubated overnight in primary antibody 
at 4ºC diluted in blocking solution.  Primary antibodies used were: anti-poly-Q (MW1, 
Coriell, 1:500 or 3B5H10, Sigma, 1:1,000), anti-huntingtin (MAB2166, EMD Millipore, 
1:1,000 or Ab1, 1:1,000) 25, anti-DARPP32 (#ab40801, Abcam, 1:10,000), anti-actin 
(A4700, Sigma, 1:1,000), and anti-spectrin (MAB1622, EMD Milliopore, 1:4,000). Blots 
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were washed in TBST, incubated in peroxidase labeled secondary antibodies (Jackson 
Immunoresearch) diluted 1:5000 in blocking solution for 1 hour at room temperature, 
washed in TBST and incubated in SuperSignal West Pico Chemiluminescent Substrate 
(Pierce #34080).  Images were obtained with a CCD imaging system (Alpha Innotech) 
and Hyperfilm ECL (GE Healthcare).  Densitometry was performed on the digital images 
using ImageJ software (NIH).  Statistical analysis was performed using upaired t-tests 
and results were expressed as mean value for the injected side. 
Immunohistochemistry for DARPP32, NeuN, and Iba1 
To quantify the DARPP32 positive cells, every twentieth section was incubated for three 
minutes in 3% hydrogen peroxide in 1x PBS, twenty minutes in 0.5% Triton-X-100, and 
then four hours in 1.5% normal goat serum (Vector Labs, S-1000) in 1x PBS.  Sections 
were incubated in anti-DARPP32 (AbCam, ab40801, 1:10,000 dilution) in 1.5% normal 
goat serum overnight at 4˚C.  Sections were then incubated in biotinylated goat, anti-
rabbit IgG antibody (Vector Labs, AP-1000, 1:200 dilution) in 1x PBS for 10 minutes.  
The sections were incubated with 2% Elite A and 2% Elite B reagent from the Vectastain 
Elite ABC Kit (Vector Labs, PK-6100) in 1x PBS for five minutes.  The Metal Enhanced 
DAB kit (ThermoFisher Scientific, 34065) was used to visualize the DARPP32 positive 
cells.  The sections were incubated in 1x 3, 3’-diaminobenzidine in stable peroxide 
buffer. 
To quantify the NeuN positive cells, every twentieth section was incubated for three 
minutes in 3% hydrogen peroxide in 1x PBS, twenty minutes in 0.5% Triton-X-100, and 
then overnight in 1.5% normal goat serum (Vector Labs, S-1000) in 1x PBS at 4˚C 
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overnight.  The sections were incubated in anti-NeuN (Chemicon, MAB377, 1:1,000 
dilution) in 1.5% normal goat serum for one hour at 4˚C.  The sections were then 
incubated for 40 minutes in a fluorescent AF594 goat, anti-mouse IgG (ThermoFisher 
Scientific, A-11005, 1:2,000 dilution) to visualize the NeuN positive cells. 
To quantify the Iba1 positive cells, every twentieth section was incubated for one hour in 
a solution of 5% normal goat serum (Vector Labs, S-1000), 1% bovine serum albumin 
(Sigma, A-3059), 0.2% Triton-X-100, and 0.03% hydrogen peroxide in 1x PBS.  The 
sections were incubated in anti-Iba1 (Wako Chemicals, 019-19741, 1:1,000 dilution) in 
5% normal goat serum (Vector Labs, S-1000) and 1% bovine serum albumin (Sigma, A-
3059) at 4˚C overnight.  Sections were incubated in biotinylated goat, anti-rabbit IgG 
antibody (Vector Labs, AP-1000, 1:200 dilution) in 1x PBS for ten minutes.  The sections 
were incubated with 2% Elite A and 2% Elite B reagent from the Vectastain Elite ABC 
Kit (Vector Labs, PK-6100) in 1x PBS for five minutes.  The Metal Enhanced DAB kit 
(ThermoFisher Scientific, 34605) was used to visualize the reaction by incubating section 
in 1x 3’,3-diaminobenzidine in stable peroxide buffer.  
The quantification of DARPP32 and Iba1 positive cells in the left and right hemisphere of 
the brain was done by taking images (20x for DARPP32 and 40x for Iba1) with a Nikon 
Eclipse E600 microscope of each section.  In order to consistently capture images 
between different sections, the first image was captured in the medial, dorsal edge of the 
striatum and the stage was moved 0.5cm toward the ventral edge.  Once the ventral edge 
was reached, the stage was moved 0.5cm laterally and 0.5cm dorsally until ten images 
16 
 
were captured.  Random numbers were assigned to each image to eliminate bias when 
quantifying cells.  The cells were counted using ImageJ software (NIH). 
The quantification of NeuN positive cells was performed using the Nikon Eclipse E600 
with a Chiu Technical Corporation Mercury 100-W lamp at 60x.  The stereological 
method used for capturing DARPP32 and Iba1 images was also used to quantify the 
NeuN positive cells.   
The area of the striatum, caudate, and putamen for each section was measured by 
manually circling the DARPP32 stained regions using ImageJ software (NIH) on the 
injected and non-injected sides of every twentieth section through the striatum (29-35 
sections per side per animal).  The observer was blinded to the conditions.  Total volume 
for each region was determined by multiplying the area by the section thickness (40 
microns) by the number of sections between slides (20) and adding together for each 
animal.  Statistical analysis was performed using Microsoft excel, paired and unpaired t-
tests, n=3 or 4 animals per group.     
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Results  
Vector genome were widely distributed in the neostriatum 
We previously reported silencing of an expanded mouse huntingtin in a knock-in model of HD 14 
and of the human mHTT transgene mRNA in a transgenic mouse model of HD 17. We 
unilaterally injected the striatum in two cohorts of HD sheep (study 1 and study 2). In study 1, 
the sheep were injected at 8-9 months of age with scAAV9-U6-miRHTT (AAV9miRHTT) or 
scAAV9-CΒA-empty (AAV9), where a non-coding sequence is inserted between the promoter 
and the poly-A signal. In study 2 the sheep were injected at 14 months of age with scAAV9-
CΒA-miRHTT or scAAV9-CΒA-empty (AAV9). The brains were harvested one and six-months 
after AAV9 administration. Vector genome copies were determined in a subset of regions 
(Figure S1) by droplet digital PCR (ddPCR, Figure 1). The genome copies were highest in the 
caudate and putamen on the injected compared to the non-injected side and were at the highest 
levels in the scAAV9-U6-miRHTT treated group at 1 and 6 months post-injection. Small amounts 
of vector genome were present in the cortex and liver, but were undetectable in the adrenals 
(Figure 1).  
A single administration of scAAV9-miRHTT reduced the human mutant huntingtin mRNA in 
caudate and putamen at one and six-months post-injection 
We measured HTT mRNA in the anterior and medial striatum using a branched DNA assay that 
specifically recognizes human and not sheep HTT mRNA 24. At one-month post-injection in the 
medial 1 block (Figure S1), scAAV9-U6-miRHTT (study 1) reduced human HTT mRNA by more 
than 50% in both the caudate and putamen (Figure 2). No significant silencing was detected in 
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the anterior striatum (Figure 2), which was farthest from the injection site (Figure S1). At six-
months post-injection, mRNA silencing was pronounced in the caudate (Figure 2).  
At one-month post-injection, AAV9-CβA-miRHTT (study 2) silenced HTT mRNA by greater than 
50% in the caudate, 35% in the putamen and 20% in the anterior striatum (Figure 2). Six-months 
post-injection we observed 40-60% silencing in the caudate, up to 40% silencing in the putamen 
(Figure 2) Interestingly, we observed no silencing in the lateral anterior striatum (area 1) but a 
non-significant trend towards lowering in the medial anterior striatum (area 2) indicating that 
there could be differences in silencing within a single block. This may explain some of the 
observed variability in the data. There was no significant silencing of the endogenous sheep HTT 
mRNA (Figure S2A). 
Western blot assay and Meso Scale Discovery (MSD) immunoassay show that AAV9-
miRHTT reduced human mutant huntingtin protein in the caudate and putamen 
HTT protein was detected by electrochemiluminescence sandwich assay (MSD, Figure 3) 26 and 
Western blot (Figure 4) in the same sample preparations. Since antibodies that detect mHTT may 
have different sensitivities and selectivities, we used multiple antibodies: 3B5H10, MAB2166 
and MW1 to detect human mHTT protein (Table 1). In the HD transgenic sheep MAB2166 
recognizes only human huntingtin and not sheep HTT 22. 3B5H10 preferentially detects mHTT 
(mutant HTT) compared to normal HTT and MW1 preferentially recognizes the expanded 
polyglutamine region in HTT 27 and was used for Western blotting and for detection of mHTT in 
the MSD assay.  
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Results with the MSD assay using MW1 for detection showed that scAAV9-U6-miRHTT 
treatment (study 1) significantly lowered mHTT protein levels in the caudate, putamen, and 
anterior striatum at one and six-months post-treatment (Figure 3). Western blotting using 
3B5H10 indicated that one-month after treatment, miRHTT significantly reduced mHTT protein 
in the caudate, putamen and anterior striatum when compared to injection with AAV9 lacking 
the miRNA (Figure 4). At six-months post-treatment there was a significant reduction of mHTT 
protein in the putamen. Data are summarized in Table 1. 
In study 2, the MSD assay showed that AAV9-CβA- miRHTT reduced mHTT protein by greater 
than 40% in caudate at one-month post-injection and in caudate, putamen and anterior striatum 6 
months after treatment (Figure 3). Western blotting using 3B5H10 indicated significant lowering 
of mHTT in the putamen at one month and in the putamen area 1 and anterior striatum area 1 at 
six months (Figure 4). Table 1 compares the mean percent lowering of mHTT detected by 
Western blot with three anti-mHTT antibodies (3B5H10, 2166, and MW1) and by MSD assay. 
All three antibodies in Western blot analysis detected significant mHTT lowering in multiple 
neostriatal regions in study 2 (49% to 81%). Results of mHTT lowering by MSD assay were 
consistent when two samples from the same striatal region were analyzed in study 2. A 
comparison of the results by Western blots and by MSD assays with MW1 in study 2 are also 
noteworthy. There was good agreement between these two different methods of mHTT detection 
in the magnitude of mHTT lowering. 
By Western blot analysis, the cortex overlying the AAV9-miRHTT injected striatum did not show 
a decline in mHTT protein levels compared to the AAV9 injected cortex (Figure S3A) nor was 
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there a reduction of mHTT protein in caudate or putamen on the contralateral, non-injected side 
(Figure S3B).  
An important question was whether treatment with AAV9-miRHTT against the human HD gene 
affected the levels of endogenous sheep HTT. We compared directly the levels of the human 
transgene mHTT with levels of endogenous sheep HTT by Western blot analysis by taking 
advantage of differences in migration of the two proteins on SDS PAGE (Figure S2B). Western 
blot analysis with Ab1 antibody, which recognizes HTT1-17, showed that unlike human mHTT, 
the endogenous sheep HTT was not lowered by treatment with miRHTT (Figure S2B).  
DARPP32 labeled neurons and striatal volume were unaffected by miRNA treatment 
DARPP32 immunoreactivity can be used as a marker for the presence of medium spiny 
neurons. To examine the safety of injection of the AAV vectors, we performed 
immunohistochemistry for DARPP32 (representative images figures S4, S5) and counted 
the number of DARPP32 positive cells within every twentieth section in the striatum. 
There was no significant difference between the number of cells in the AAV9-miRHTT 
treated and AAV9 control treated groups (Table S1). Although there is a trend toward 
loss of DARPP32 positive cells between 1 and 6 months in the first study, this difference 
did not reach statistical significance, nor did we detect differences between wild-type and 
HD animals in study 2. The number of cells staining for NeuN, a marker of neuronal cells 
also showed no significant difference between groups. Striatal volumes were determined 
using cross-sectional area measurements of striatum in DARPP32 labeled sections and 
were found to be unchanged compared to controls after miRNA treatment (Table S2). 
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A transient increase in activated microglia occurred after direct injection with AAV9-miRHTT and 
AAV9 control 
We examined immuno-histochemical localization of Iba1 (examples are shown in figures 
S4, S5), a protein which is localized to microglia and upregulated upon their activation 28. 
Labeled cells were identified based on morphology as resting or activated microglia 
(Table S3). Injection of scAAV9-U6-miRHTT or the corresponding control vector 
increased the number of activated microglia on the injected side at one-month post-
treatment. On the non-injected side, activated cells comprise less than 1% of the total 
number of Iba1 positive cells, whereas on the injected side they are 49%-58% of the total. 
Six-months after treatment the injected and non-injected sides were indistinguishable. In 
the second study, we examined the microglial response only at the study end point (6 
months). At this time there is a trend toward higher Iba1 positive activated microglia in 
the AAV9 (control) injected HD sheep when compared to the AAV9 (control) injected 
wild-type animals, but this did not reach statistical significance. We cannot exclude the 
possibility that HD and control sheep have a small difference in microglia response at this 
age, which the current study is not powered to detect. Additional experiments are 
required to rule out this hypothesis. The number of Iba1 positive activated microglia is 
small, between 2% and 12% of the total number of Iba1 positive cells and there was no 
significant difference between any of the groups. The findings suggest that the transitory 
increase in activated microglia is independent of AAV cargo and can occur with any 
vector or with surgery alone. 
AAV9-miRHTT treatment did not affect blood counts, electrolytes, or liver and kidney function 
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Blood samples were taken at four times: baseline (pretreatment), 28 (or 30) days, 90 
days, and 180 days post treatment.  We measured a complete blood count, electrolytes, 
liver and kidney function tests (Table S4). No meaningful changes in any of these 
measurements were found between AAV9-miRHTT injected sheep and controls.  In 
addition, there were no differences in weight or normal movement between groups. 
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Discussion 
This study addressed important concerns for therapy of Huntington’s disease. First, a single 
treatment with the scAAV9-miRHTT effectively lowered mutant human huntingtin in the 
neostriatum of an animal with a large brain. Second, lowering huntingtin mRNA and protein has 
been reported in rodent models (3,4,6,11), but only a handful of studies focused on the full length 
mutant huntingtin (11, 26). The transgenic sheep used here is the only large animal with a full-
length human mHTT. A critical advantage of this HD model is that additional downstream 
exons, compared to N-terminal models of disease, are available for miR targeting. Third, mutant 
human huntingtin reduction could be achieved and sustained with two different promoters, 
confirming the robustness of the miRHTT activity. 
Lowering mutant human huntingtin protein was the goal of the miRNA mediated silencing. This 
goal was achieved. Mutant human huntingtin mRNA was reduced, but somewhat less 
consistently than huntingtin protein lowering which was detected by Western blot with multiple 
antibodies and by MSD assay. We offer several speculations that might account for the more 
consistent huntingtin protein reduction compared to mRNA.  Huntingtin mRNA may have a 
compartmental distribution in neurons, exhibiting cytoplasmic and nuclear localization or 
differential distribution to cell bodies and axons or dendrites. These different pools of mRNA 
may respond to miRNA silencing differently. Furthermore, the cumulative effect of small 
differences in injection and sampling site may increase the variability of measurements. Samples 
for mRNA, protein and DNA vector genome analysis were taken from adjacent sites but the 
block size was reasonably large. We showed that using our method, there can be differences in 
observed silencing within a single sample block. In future studies, we would recommend 
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freezing samples in smaller, single use blocks and measuring protein and RNA from the same 
sample. Finally, mRNA might be less stable and the methods used to measure it less 
reproducible than protein. These observations highlight the importance of measuring both 
mRNA and protein, if possible, by more than a single method. Measurements of protein and 
mRNA represent bulk amounts in brain regions, rather than in individual cells.  Huntingtin 
mRNA estimations in neurons vary14 and huntingtin protein variance has not been established. In 
the current study we present a composite of mRNA silencing. Using these measures we cannot 
determine the extent of mHtt reduction on a cellular or subcellular level. 
Within the brain the vector was mainly concentrated near the injection site between the caudate 
and putamen, indicating that the local spread by convection enhanced delivery surmounted 
anatomic restraints that might be imposed by the internal capsule. Much lower steady state levels 
of AAV9 vector genome were detected in the ipsilateral cortex – it will be interesting in a 
follow-up study to detect vector genome in neurons collected by laser capture. We speculate that 
a higher amount of AAV9 volume or titer might have huntingtin lowering properties in cortex. 
The small amount of AAV9 vector genome in the contralateral neostriatum was not associated 
with mutant huntingtin protein change. Outside of the brain, we detected only a little AAV9 in 
the liver. 
The transgenic HD sheep offer a value-added to study of mutant huntingtin protein lowering. 
Further characterization of the model, including a detailed analysis of the number of DARPP32 
positive neurons and microglia activation, may reveal additional phenotypes which will further 
enhance the value of the model. However, concerns about huntingtin protein lowering remain. In 
addition to the human huntingtin transgene, the model has two sheep huntingtin alleles. Our 
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approach successfully reduced mutant human huntingtin and did not affect the sheep huntingtin. 
Most current and broadly applicable Htt targeting therapies affect both huntingtin alleles. Allele 
specific artificial miRNA would require a complex strategy involving generation of multiple 
AAV-miRs targeted to single nucleotide polymorphism heterozygosities, and would apply to 
only a subset of patients. A broad artificial miR would reduce the toxic moiety and could be 
beneficial for all patients but it is not yet clear if long-term elimination of huntingtin is safe 29,30.  
A future study in non-human primates with the same miRHTT, which would silence both alleles 
would help to clarify this issue. In this study, we focused on young sheep that lack huntingtin 
inclusions or neuronal loss.  For the most part, HD is a disease of adults; study of older sheep 
would have virtue, especially if the HD transgenic sheep were to develop signs of disease or 
neuropathology. 
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Figure and Table Legends 
Figure 1. AAV vector genomes in control (AAV9) and treated (AAV9miRHTT) treated 
animals. In brain samples (A), red represents the injected side and blue, the non-
injected. Results from liver and adrenals are reported in B. Vector genomes were 
measured by digital droplet PCR using genomic HPRT as the reference gene. The 
values are plotted on a log scale. 
Figure 2. scAAV9-anti-HTT-6433 reduces human mutant huntingtin mRNA in the 
striatum. Data shown are the signal for HTT mRNA normalized to sheep calnexin 
(CANX). Asterisks indicate significant differences in means between treatment groups 
(AAV9 or AAV9miRHTT) at p≤0.03 with unpaired t-tests. The U6-promoter driven artificial 
miRNA significantly lowers human mutant HTT mRNA caudate and putamen at 1 month 
post-injection and in putamen at 6 months post-injection. The CΒA-promoter driven 
artificial miRNA lowers the HTT mRNA in the caudate, putamen and anterior striatum at 
1 month post-injection and in the caudate and putamen at 6 month post-injection. The 
medial region of the caudate, lateral putamen and anterior striatum were examined in 
the analysis. 
Figure 3. Human mutant HTT levels detected by MSD assay at 1 and 6 months post-
injection in study 1 (U6 promoter) and study 2 (CΒA promoter). Graph shows 
distribution of individual values and means (horizontal bars) for sheep treated with either 
AAV9 (control) or AAV9-miRHTT. Results are shown for different striatal regions 
(caudate, putamen and anterior striatum). Asterisks * indicate significant difference on 
the injected side between AAV9 and AAV9-miRHTT at p<0.05 based on unpaired t-tests. 
 
Figure 4. Western blot assays show that AAV9-miRHTT reduces the human mutant 
huntingtin protein in the striatum. A. Sample Western blots of putamen from Studies 1 
and 2 show mutant HTT detected with antibody 3B5H10 and actin as loading control. B. 
Graph shows distribution of individual values and mean (horizontal bar) for sheep 
treated with either AAV9 (control) or AAV9-miRHTT. Shown are results for different 
striatal regions (caudate, putamen and anterior striatum) in studies 1 and 2 and 1 and 6 
months post-injection. In study 2, 6 months post-injection two areas (Area 1 and 2) were 
examined in each region. Asterisks indicate significant difference on the injected side 
between AAV9 and AAV9-miRHTT at p<0.05 based on unpaired t-tests. 
 
Table 1. Mean percent of mutant huntingtin protein lowering by Western blot and MSD 
assays in Studies 1 and 2. The human mutant huntingtin protein was measured by 
Western blot with anti-htt polyQ antibody 3B5H10 in study 1 and antibodies 3B5H10, 
MAB2166 (anti-HTT443-456), which does not recognize sheep HTT (Reid et al., 2013), 
and anti-polyQ monoclonal antibody MW1 in study 2.  In the MSD assays MW1 was 
used as the detection antibody. This table reports the mean percent mHTT lowering for 
the caudate, putamen, and anterior striatum. Percent lowering was calculated by 
dividing the average signal for the injected side in the AAV9miRHTT treated sheep by the 
average signal for the injected side in the AAV9 alone treated animals. Study 2, 6 
months post-injection, 2 areas per region were analyzed. *p<0.05, **p<0.001, unpaired t 
test, N= Study 1, 1 month, 6 AAV9, 8 AAV9-miRHTT; Study 1, 6 months, 6 AAV9, 7 
AAV9-miRHTT; Study 2, 1 month, 4 AAV9, 4 AAV9-miRHTT; Study 2, 6 months, 6 AAV9, 
6 AAV9-miRHTT. 
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Table 1. Mean percent of mutant huntingtin protein lowering by Western blot and MSD assays 
in Studies 1 and 2. The human mutant huntingtin protein was measured by Western blot with 
anti-htt polyQ antibody 3B5H10 in study 1 and antibodies 3B5H10, MAB2166 (anti-HTT443-
456), which does not recognize sheep HTT (Reid et al., 2013), and anti-polyQ monoclonal 
antibody MW1 in study 2.  In the MSD assays MW1 was used as the detection antibody. This 
table reports the mean percent mHTT lowering for the caudate, putamen, and anterior striatum. 
Percent lowering was calculated by dividing the average signal for the injected side in the 
AAV9miRHTT treated sheep by the average signal for the injected side in the AAV9 alone treated 
animals. 
 
Study 2, 6 months post-injection, 2 areas per region were analyzed. 
*p<0.05, **p<0.001, unpaired t test, N= Study 1, 1 month, 6 AAV9, 8 AAV9-miRHTT; Study 1, 6 
months, 6 AAV9, 7 AAV9-miRHTT; Study 2, 1 month, 4 AAV9, 4 AAV9-miRHTT; Study 2, 6 
months, 6 AAV9, 6 AAV9-miRHTT. 
 
 
Table 1. Mean percent of mutant huntingtin protein lowering by Western blot and MSD assays in Studies 1 and 2.  
Study# (promoter) Study 1 (U6) Study 2 (CΒA) 
Assay  
mutant htt antibody 
Western 
blot  
(3B5H10) 
MSD 
MW1  
Western blot 
(3B5H10) 
Western blot 
(MAB2166) 
Western blot  
(MW1) 
MSD 
MW1 
Post-injection Interval 
(months) 1 6 1 6 1 6 1 6 1 6 1 6 
Caudate 78** 30 71** 74** 16 30, 43 61 46, 58* 
50
* 65*, 70 43* 40*, 47* 
Putamen 61* 47* 
73*
* 50* 
40
* 55*, 44 
68
* 
65*, 
67* 54 
51*, 
56* 42 63**, 56** 
Anterior Striatum 63** 22 49* 33 46 60**, 48 46 
81*, 
62* -8 
74*, 
53* 22 62**, 67** 
Supplementary Materials 
Fig. S1. Schematic of sheep brain dissected in the coronal plane.  
Fig. S2. Quantification of artificial miRNA guide strand. 
Fig. S3. Levels of endogenous sheep htt mRNA and protein in AAV9 and AAV9miRHTT treated 
sheep. 
Fig S4. Human mutant HTT protein in the cortex, contralateral caudate and putamen. 
Table S1. Number of DARPP32 and NeuN positive cells. 
Table S2. Striatal volume. 
Table S3. Number and classification based on morphology of Iba1 positive cells. 
Data file S1. Clinical pathology and complete blood counts for all sheep. 
  
 Figure S1. Schematic of sheep brain dissected in the coronal plane. A. The brain was placed in a 
custom built brain matrix and cuts were made so that the entire striatum was contained within 4, 
6mm blocks. The typical trajectory is illustrated in B. Distance is 2.49cm from the dural surface. 
C. The anterior block contains the anterior portion of the striatum which is not divided by the 
internal capsule and the medial blocks, to which the injection is targeted have a defined putamen 
and caudate. D. The green line is the exact trajectory corresponding to the saggital view in B. 
 
 Figure S2. Levels of endogenous sheep htt mRNA and protein in AAV9 and AAV9miRHTT 
treated sheep. A. Sheep htt mRNA levels were determined as described in methods and are 
expressed relative to sheep calnexin (Canx). Shown are results from Study 2. There is no 
difference in endogenous sheep htt mRNA levels between AAV9 and AAV9miRHTT treated 
groups. B. Levels of endogenous sheep huntingtin and human mHTTprotein detected with anti-
htt1-17 antibody (Ab1) in putamen from Study 2, 6 months post-injection. Sample Western blot 
shows signal for wt htt (arrow) and human mutant htt (arrowhead) for the injected and non-
injected sides of the brain in 4 different sheep injected on one side with AAV9miRHTT. Graph 
shows mean wt sheep htt and human mHTT signals determined from the densitometry as percent 
injected side to non-injected side. Note that treatment with AAV9miRHTT does not affect levels 
of endogenous sheep huntingtin protein but significantly reduces levels of human mHTT. 
Asterisk indicates p=0.005 with unpaired t-test. 
 Figure S3. mHTT levels are unchanged in the ipsilateral cortex and contralateral caudate 
putamen of miRHTT injected sheep striatum A. Graph shows mean levels of mHTT normalized to 
actin in the cortex ipsilateral to the miRHTT injected striatum. Data are from study 1, 1 and 6 
months post-injection, NS, based on unpaired t-test.  B, Bar graph shows levels of mHTT 
normalized to actin in the caudate and putamen contralateral to the miRHTT   injected striatum.   
Data are from study 1, 1 and 6 months post-injection, NS, based on unpaired t-test. 
 
Figure S4. Representative examples of immunohistochemical staining of injected sheep 
used to count cells in tables S1 and S3. Peroxidase immunohistochemistry with  DARPP32 
antibody to label medium spiny neurons and the Iba-1 antibody to label microglial cells in the 
striatum of transgenic and normal sheep. A. Study 1 (U6 promoter) transgenic sheep 6 months 
post injection. B. Study 2 (CΒA promoter) transgenic sheep 6 months post injection. C. Study 2 
(CΒA promoter) wild type sheep 6 months post injection. We found no differences between 
groups. 
  
  
 
Figure S5. Representative examples of immunohistochemical staining of non-injected sheep 
used to count cells in tables S1 and S3 Peroxidase immunohistochemistry with the DARPP32 
antibody to label medium spiny neurons and the Iba-1 antibody to label microglial cells in the 
striatum of transgenic and wild type sheep that did not receive an injection.  These animals 
were age-matched to those in the AAV9 and AAV9 miRHTT groups from study 2 (CΒA 
promoter). 
 
  
  
Study# 
(promoter) 
Group  Post-injection 
interval 
(months), 
number 
Side # of 
DARPP32 
positive cells 
# of NeuN 
positive 
cells 
Study 1 (U6) 
 
HD 
AAV9  
1 
(n=3) 
inj 4201±389   
non-inj 4056±488   
6 
(n=3) 
inj 2819±614 1185±70 
non-inj 3314±364 1368±180 
AAV9 
miRHTT  
1 
(n=4) 
inj 4327±1444   
non-inj 4587±838   
6 
(n=3) 
inj 3884±1222 1547±315 
non-inj 4149±924 1633±262 
Study 2 (CΒA) 
 
HD 
AAV9 
6 
(n=3) 
inj 2459±85 1111±314 
non-inj 2324±347 1184±330 
AAV9 
miRHTT  
6 
(n=3) 
inj 2061±321 1404±61 
non-inj 2084±460 1499±46 
No 
Injection  
6 
(n=3) 
left 1852±232 1440±76 
right 2047±306 1183±220 
Study 2 (CΒA) 
 
WT 
AAV9 
6 
(n=3) 
inj 2121±96 1157±180 
non-inj 2148±146 1106±86 
AAV9 
miRHTT  
6 
(n=3) 
inj 1799±223 1285±1511 
non-inj 1895±327 1434±142 
No 
Injection  
6 
(n=3) 
left 1963±181 1188±328 
right 2101±219 1056±258 
Table S1. Number of DARPP32 and NeuN positive cells. Data were analyzed by paired t-test 
(injected to non-injected side). A significant difference was found between injected and non-
injected sides only in WT sheep injected with AAV9-CβA-miRHTT at six-months post injection, 
1p=0.002 by paired t-test. 
  
 Volume (mm3),  
Mean±SD 
Study 1 (U6) Study 2 (CΒA) 
1 month 
post-
injection 
6 months 
post-
injection 
6 months 
post-
injection 
Caudate 
HD 
AAV9 
inj 293±54 241±13  
non-inj 300±48 248±17  
% inj/non-inj 97.3±4.2 97.2±3.2  
AAV9 miRHTT 
inj 257±48 302±15 280±79 
non-inj 290±48 325±33 304±49 
% inj/non-inj 88.6±9.3 93.8±15 91.1±12 
WT  AAV9 miRHTT 
inj   283±671 
non-inj   309±65 
% inj/non-inj   91.4±2.7 
Putamen 
 
HD  
AAV9 
inj 298±46 247±33  
non-inj 307±52 274±11  
% inj/non-inj 97.0±1.4 90.3±13  
AAV9 miRHTT 
inj 278±57 318±392 281±10 
non-inj 285±50 340±45 314±21 
% inj/non-inj 97.5±8.9 93.6±1.2 89.9±6.9 
WT  AAV9 miRHTT 
inj   292±45 
non-inj   329±63 
% inj/non-inj   89.2±3.7 
Striatum 
 
(Rostral 
pole + 
Caudate  + 
Putamen) 
HD  
AAV9 
inj 1041±172 947±28  
non-inj 1034±150 1006±49  
% inj/non-inj 101±2.3 94.3±5.6  
AAV9 miRHTT 
inj 1023±85 1030±313 1165±145 
non-inj 1037±96 1110±31 1222±116 
% inj/non-inj 98.8±4.7 92.8±1.7 95.1±4.0 
WT  AAV9 miRHTT 
inj   1159±76 
non-inj   1210±32 
% inj/non-inj   95.7±3.8 
Table S2. Striatal volume. Volume was determined from cross-sectional areas of 29-35 40 µm 
sections per side per animal, N=3 sheep per group. 1p=0.01, 2p=0.03, 3p=0.02, using a paired t 
test. 
  
Study# 
(promoter) 
Group  Post-
injection 
interval 
(months) 
Side # of Iba1 
activated 
microglia 
# of Iba1 
resting 
microglia 
Total # 
Iba1 
positive 
cells 
Study 1 (U6) HD 
AAV9  
1 inj 253±178 180±1023 433±168 
non-inj 2.0±2 305±70 307±68 
6 inj 29±19 351±104 380±123 
non-inj 12±6 377±214 388±219 
AAV9 
miRHTT  
1 inj 195±2 201±774 396±135 
non-inj 2.8±3 347±116 350±113 
6 inj 29±81 279±202 308±194 
non-inj 6.7±4 311±148 318±144 
Study 2 (CΒA) HD 
AAV9 
6 inj 38±10 263±31 301±234 
non-inj 23±3 248±29 271±32 
AAV9 
miRHTT  
6 inj 10±4 240±38 251±37 
non-inj 6.0±4 260±32 266±36 
No 
Injection  
6 left 8.3±5 256±90 265±85 
right 13±17 192±112 204±100 
Study 2 (CΒA) WT 
AAV9 
6 inj 16±42 288±39 303±35 
non-inj 7.0±4 256±50 263±46 
AAV9 
miRHTT  
6 inj 22±18 261±29 283±26 
non-inj 8.7±7 303±59 312±55 
No 
Injection  
6 left 10±12 246±108 256±96 
right 9.3±8 298±63 307±69 
Table S3. Number and classification based on morphology of Iba1 positive cells. Statistical 
analysis was done by paired t-test (injected side vs. non-injected side). A significant increase in 
activated microglia on the injected side compared to non-injected side was found in HD sheep 
injected with AAV9-U6-miRHTT (1 p=0.01) and in WT sheep injected with AAV9 (2 p=0.006) at 
six-months. A significant decrease in resting microglia was found at one-month in HD sheep 
injected with both AAV9 (3 p=0.05) and AAV9-U6-miRHTT (4 p=0.04) and a significant increase 
in total microglia was found in HD sheep injected with AAV9 at six-months in study 2 (4 
p=0.04). All analyses were done by paired t-test comparing injected to non-injected side. 
 Table S4. Clinical pathology and complete blood counts for all sheep (excel file data S1).  
 
 
 
